Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2026 07:45 ET | Source: Profound Medical Corp.

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
January 06, 2026 07:32 ET | Source: Rail Vision Ltd.

Rail Vision Advances Indian Market Entry with Demonstration for Senior Governmental Officials from Multiple Government Departments

Ra’anana, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and...
January 06, 2026 07:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...
January 06, 2026 07:30 ET | Source: Nayax Ltd.

Nayax to Showcase New Digital Commerce Products for Specialty and Fashion Retail at NRF 2026

HERZLIYA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement, payments, and loyalty platform designed to help merchants scale their...
January 06, 2026 07:30 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing...
January 06, 2026 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “Phase 2 Study of Zervimesine (CT1812) in Participants...
January 06, 2026 07:30 ET | Source: Repligen Corporation

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has...
January 06, 2026 07:30 ET | Source: Edible Garden AG Incorporated

Edible Garden Preliminary Holiday Sales Surge 26.4% Year-Over-Year During Key Time Period

BELVIDERE, NJ, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture...
January 06, 2026 07:30 ET | Source: BullFrog AI Holdings, Inc.

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and...
January 06, 2026 07:30 ET | Source: ProKidney

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...